Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an announcement.
Recce Pharmaceuticals Ltd. has received a Notice of Acceptance from the China National Intellectual Property Administration for its patent on anti-infectives, extending its patent portfolio to the world’s second-largest pharmaceutical market. This development is significant as it validates Recce’s innovative treatments for various infections and enhances its market positioning, potentially benefiting stakeholders by tapping into a growing Chinese antibiotic market projected to expand at a CAGR of 5.7% from 2025 to 2030.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is a leading developer in the pharmaceutical industry, specializing in a new class of synthetic anti-infectives. The company focuses on creating innovative treatments for bacterial and viral infections, with products like RECCE® 327 and RECCE® 529. Recce is expanding its market presence with patents in multiple countries, including Australia, Canada, Israel, Japan, and now China.
Average Trading Volume: 211,997
Technical Sentiment Signal: Sell
Current Market Cap: A$75.98M
For a thorough assessment of RCE stock, go to TipRanks’ Stock Analysis page.